Vetter Advances Next-Generation Tamper-Evident Syringe Closure Towards Launch
The company has advanced its next‑generation tamper‑evident syringe closure from design finalization to industrialization ahead of a planned 2027 launch to strengthen its position in prefilled drug‑delivery solutions.
Global CDMO, Vetter, has reached a series of key milestones in the development and launch preparation of V-OVS next, its next-generation tamper-evident closure system for prefilled syringe-based therapies. Developed from extensive market feedback and unveiled at Pharmapack 2025, the closure is now design-finalized, progressing through industrialization, and on track for commercial availability in 2027 (1).
V-OVS next has been engineered as an evolution of the original V-OVS closure, offering an enhanced user experience and a differentiating look and feel, with a safe and effective closure system as confirmed via a functional study. The new system introduces intuitive handling, innovative functionality, and a premium design. The closure fits a wide range of syringe formats, while sharing the same contact materials and standard tip cap rubber formulations as its predecessor to simplify switching and lifecycle upgrades.
For drug developers and device users, the benefits of the next-generation tamper-evident closure systems span safety, ease of use, and product differentiation. The closure is designed to enhance protection and usability for ophthalmology, aesthetic injectables, diluents, and biologics, to help manufacturers support safe and effective handling while offering a more premium presentation to clinicians and patients.
“Our goal was to combine safety, usability, and design in a way that truly benefits the user of the system,” said Claus Feussner, Senior Vice President Development Service at Vetter, in a company press release (1). “The positive results from both usability and performance evaluations confirm that V-OVS next delivers on these objectives.”
Looking ahead, Vetter has initiated industrialization and plans to supply its primary syringe glass partners with NFHU materials for implementation and testing across multiple syringe formats. Commercialization is scheduled for 2027, with Vetter planning to continue offering both V-OVS and V-OVS next post-launch to expand its portfolio of syringe-based solutions.
“With the first biopharma customers already giving positive feedback, we’re excited to see market uptake by some glass suppliers,” added Lars Hahn, Senior Vice President Global Sales Organization at Vetter, in the press release (1). “We’ve already had successful conversations with multiple value chain partners and received consistently encouraging responses that reinforce our confidence in this launch.”
Strategically, V-OVS next strengthens Vetter’s position as a leading CDMO partner for prefilled syringe drug-delivery systems. By pairing advanced closure technology with its existing capabilities in drug product development, clinical and commercial filling, and assembly and packaging, Vetter can support customers in bringing safer, more user-centric syringe presentations to market.
The ability to offer both legacy and next-generation closures, with straightforward upgrade pathways, enhances Vetter’s value proposition to pharma and biotech companies seeking to differentiate products, manage lifecycle updates, and improve patient safety, comfort, and compliance within an integrated CDMO offering.
Reference
Vetter. Vetter Reaches Key Launch Milestones for the V-OVS next Tamper-Evident Syringe Closure System. Press Release, Jan. 15, 2026.